Efficacy and Safety of Sulfonylurea Use in Permanent Neonatal Diabetes Due to <i>KCNJ11</i> Gene Mutations: 34-Month Median Follow-Up

Abstract

In summary, the switch from insulin therapy to SU treatment in PNDM related to KCNJ11 mutations was found to be an efficient and safe therapeutic method over a period of 34-month median follow-up. Although no serious side effects were associated with SU treatment, their use in Kir6.2 PNDM requires further attention, particularly in children, adolescents, and patients with advanced chronic diabetes complications.